CAS 205923-56-4

ImmunoglobulinG1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 g1-chain),disulfide with human-mouse monoclonal C225 k-chain, dimer

Description:

Immunoglobulin G1 (IgG1), specifically the anti-human epidermal growth factor receptor (EGFR) monoclonal antibody C225, is a therapeutic protein designed for targeted cancer treatment. This dimeric antibody consists of two heavy chains (g1-chain) and two light chains (k-chain) linked by disulfide bonds, which stabilize its structure. IgG1 is characterized by its ability to bind specifically to the EGFR, a receptor often overexpressed in various cancers, thereby inhibiting tumor growth and promoting apoptosis. The antibody's structure allows for effective engagement with immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Additionally, the human-mouse chimeric nature of C225 enhances its stability and reduces immunogenicity compared to fully murine antibodies. This characteristic makes it a valuable tool in cancer immunotherapy, particularly in treating head and neck cancers and other malignancies associated with EGFR overexpression. Overall, the unique properties of this monoclonal antibody contribute to its efficacy in clinical applications targeting specific cancer pathways.

Synonyms:

• C225
• Cetuximab
• EGFR antibody
• Erbitux
• Imc 225
• Imc-C 225

Cetuximab

CAS: 205923-56-4

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM).

Formula: C₁₀₇H₁₇₉N₃₅O₃₆S₇

Purity: 95 - 98.60%

Color and Shape: Liquid

Molecular weight: 152 kDa

Ref: TM-T9905

Cetuximab - Buffer solution

CAS: 205923-56-4

A monoclonal antibody against epidermal growth factor receptor (EGFR), inhibiting the binding of endogenous ligands and blocking subsequent receptor activation and intracellularr signalling. Downregulation of EGFR by cetuximab is mediated by inducing receptor internalization for degradation. In cancer, cetuximab has anti-proliferative and anti-angiogenic effects and is studied in colorectal, head and neck, squamous cell and non-small cell lung cancers.

Formula: C₆₄₈₄H₁₀₀₄N₁₇₃₂O₂₀₂₃S₃₆

Purity: Min. 95 Area-%

Color and Shape: Colorless Clear Liquid

Molecular weight: 136581.88735

Ref: 3D-FC64978